Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Follow-up Study to Assess the Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

NCT02581020 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02581020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02581020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Follow-up Study to Assess the Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
January 14, 2016
Completion date
December 8, 2020
Enrollment
344 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c virus